Ranbaxy Laboratories on Monday announced that its South Africa-based joint venture Sonke Pharmaceuticals had bagged a 913.5-million rand (about Rs.605 crore) order from the South African Government for supply of anti-HIV drugs for treatment of AIDS. The order is a part of a 4.28-billion rand national anti-retroviral (ARV) tender floated by the South African Government, Ranbaxy said in a statement here. Sonke Pharmaceuticals, a joint venture between Ranbaxy (Pty) Ltd and Community Investment Holdings (CIH), is the second-largest local supplier of generic ARV medication in South Africa. Ranbaxy holds a majority 70 per cent stake in Sonke. The medicines will be manufactured in South Africa and at Ranbaxy's facilities in India, the statement said.